AT₁-Rezeptor Blocker und ACE-Hemmer in Kombination – contra

Schlüsselwörter

ACE-Hemmer - AT₁-Rezeptor-Blocker - arterielle Hypertonie - Renin-Angiotensin-Blockade - Proteinurie - Niereninsuffizienz

Keywords

ACE inhibition - angiontensin receptor blocker - arterial hypertension - renin-angiotensin system - proteinuria - renal failure

Literatur

• 1 Kunz R, Friedrich C, Wolbers M, Mann J F. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.  Ann Intern Med. 2008;  148 30-48
• 2 Mann J F, Schmieder R E, McQueen M, Dyal L. et al . Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study).  Lancet. 2008;  372 547-553
• 3 McMurray J J, Ostergren J, Swedberg K, Granger C B. et al . Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.  Lancet. 2003;  362 767-771
• 4 Nakao N, Yoshimura A, Morita H, Takada M. et al . Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE).  Lancet. 2003;  361 117-124
• 5 Schmieder R E, Klingbeil A U, Fleischmann E H, Veelken R. et al . Additional antiproteinuric effect of ultrahigh dose candesartan.  J Am Soc Nephrol. 2005;  16 3038-3045
• 6 Yusuf S, Teo K K, Pogue J, Dyal L. et al . Telmisartan, ramipril, or both in patients at high risk for vascular events.  N Engl J Med. 2008;  358 1547-1559